EGFR-MUTANT NON-SMALL CELL LUNG CANCER
Clinical trials for EGFR-MUTANT NON-SMALL CELL LUNG CANCER explained in plain language.
Never miss a new study
Get alerted when new EGFR-MUTANT NON-SMALL CELL LUNG CANCER trials appear
Sign up with your email to follow new studies for EGFR-MUTANT NON-SMALL CELL LUNG CANCER, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New pill targets Hard-to-Treat lung cancer mutations
Disease control Recruiting nowThis study tests an experimental oral drug called VRN110755 in people with a specific type of lung cancer (EGFR-mutant non-small cell lung cancer). The drug is designed to block cancer growth by targeting the EGFR protein and certain resistance mutations, including C797S. The tri…
Matched conditions: EGFR-MUTANT NON-SMALL CELL LUNG CANCER
Phase: PHASE1, PHASE2 • Sponsor: Voronoi, Inc • Aim: Disease control
Last updated Jul 15, 2026 00:00 UTC
-
Drug duo aims to turn inoperable lung cancer into surgical candidates
Disease control Recruiting nowThis study tests whether two drugs, sacituzumab tirumotecan and limertinib, can shrink EGFR-mutant lung cancer enough to allow surgery. About 36 adults with advanced but potentially removable lung cancer will receive the combination before surgery. The goal is to see how many pat…
Matched conditions: EGFR-MUTANT NON-SMALL CELL LUNG CANCER
Phase: PHASE2 • Sponsor: Shanghai Pulmonary Hospital, Shanghai, China • Aim: Disease control
Last updated Jun 27, 2026 08:09 UTC